[go: up one dir, main page]

FR2998479B1 - Utilisation d'un ester de dha pour le traitement prophylactique et/ou curatif de la drepanocytose - Google Patents

Utilisation d'un ester de dha pour le traitement prophylactique et/ou curatif de la drepanocytose

Info

Publication number
FR2998479B1
FR2998479B1 FR1261291A FR1261291A FR2998479B1 FR 2998479 B1 FR2998479 B1 FR 2998479B1 FR 1261291 A FR1261291 A FR 1261291A FR 1261291 A FR1261291 A FR 1261291A FR 2998479 B1 FR2998479 B1 FR 2998479B1
Authority
FR
France
Prior art keywords
drepanocytosis
prophylactic
curative treatment
dha ester
dha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR1261291A
Other languages
English (en)
Other versions
FR2998479A1 (fr
Inventor
Jean Paul Caubere
Adam Frederique Lantoine
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pierre Fabre Medicament SA
Original Assignee
Pierre Fabre Medicament SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR1261291A priority Critical patent/FR2998479B1/fr
Application filed by Pierre Fabre Medicament SA filed Critical Pierre Fabre Medicament SA
Priority to MX2015006685A priority patent/MX2015006685A/es
Priority to MA38113A priority patent/MA38113A1/fr
Priority to PCT/EP2013/074863 priority patent/WO2014083059A1/fr
Priority to US14/647,364 priority patent/US20150306056A1/en
Priority to BR112015012102A priority patent/BR112015012102A2/pt
Priority to EP13795784.1A priority patent/EP2925311A1/fr
Publication of FR2998479A1 publication Critical patent/FR2998479A1/fr
Priority to IL238954A priority patent/IL238954A0/en
Priority to TNP2015000199A priority patent/TN2015000199A1/fr
Priority to ZA2015/03808A priority patent/ZA201503808B/en
Application granted granted Critical
Publication of FR2998479B1 publication Critical patent/FR2998479B1/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FR1261291A 2012-11-27 2012-11-27 Utilisation d'un ester de dha pour le traitement prophylactique et/ou curatif de la drepanocytose Expired - Fee Related FR2998479B1 (fr)

Priority Applications (10)

Application Number Priority Date Filing Date Title
FR1261291A FR2998479B1 (fr) 2012-11-27 2012-11-27 Utilisation d'un ester de dha pour le traitement prophylactique et/ou curatif de la drepanocytose
MA38113A MA38113A1 (fr) 2012-11-27 2013-11-27 Utilisation d'un ester de dha pour le traitement prophylactique et/ou curatif de la drepanocytose
PCT/EP2013/074863 WO2014083059A1 (fr) 2012-11-27 2013-11-27 Utilisation d'un ester de dha pour le traitement prophylactique et/ou curatif de la drepanocytose
US14/647,364 US20150306056A1 (en) 2012-11-27 2013-11-27 Use of a dha ester for prophylactic and/or curative treatment of drepanocytosis
BR112015012102A BR112015012102A2 (pt) 2012-11-27 2013-11-27 utilização de um éster de dha para o tratamento profilático e/ou curativo da drepanocitose
EP13795784.1A EP2925311A1 (fr) 2012-11-27 2013-11-27 Utilisation d'un ester de dha pour le traitement prophylactique et/ou curatif de la drepanocytose
MX2015006685A MX2015006685A (es) 2012-11-27 2013-11-27 Uso de un ester de dha para el tratamiento profilactico y/o curativo de la drepanocitosis.
IL238954A IL238954A0 (en) 2012-11-27 2015-05-21 Use of dha ester for preventive and/or curative treatment in sickle cell anemia
TNP2015000199A TN2015000199A1 (fr) 2012-11-27 2015-05-22 Utilisation d'un ester de dha pour le traitement prophylactique et/ou curatif de la drepanocytose
ZA2015/03808A ZA201503808B (en) 2012-11-27 2015-05-27 Use of a dha ester for prophylactic and/or curative treatment of drepanocytosis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1261291A FR2998479B1 (fr) 2012-11-27 2012-11-27 Utilisation d'un ester de dha pour le traitement prophylactique et/ou curatif de la drepanocytose

Publications (2)

Publication Number Publication Date
FR2998479A1 FR2998479A1 (fr) 2014-05-30
FR2998479B1 true FR2998479B1 (fr) 2017-04-28

Family

ID=47714308

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1261291A Expired - Fee Related FR2998479B1 (fr) 2012-11-27 2012-11-27 Utilisation d'un ester de dha pour le traitement prophylactique et/ou curatif de la drepanocytose

Country Status (10)

Country Link
US (1) US20150306056A1 (fr)
EP (1) EP2925311A1 (fr)
BR (1) BR112015012102A2 (fr)
FR (1) FR2998479B1 (fr)
IL (1) IL238954A0 (fr)
MA (1) MA38113A1 (fr)
MX (1) MX2015006685A (fr)
TN (1) TN2015000199A1 (fr)
WO (1) WO2014083059A1 (fr)
ZA (1) ZA201503808B (fr)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6946457B2 (en) * 2001-04-06 2005-09-20 The Trustees Of Columbia University In The City Of New York Methods of treating sickle cell disease
CA2634139C (fr) * 2005-12-20 2015-06-23 Cenestra, Llc. Preparations a base d'acide gras omega 3
FR2902659A1 (fr) * 2006-06-23 2007-12-28 Pierre Fabre Medicament Sa Ester de dha et son utilisation dans le traitement et la prevention des maladies cardiovasculaires
FR2949063B1 (fr) * 2009-08-11 2011-09-30 Pf Medicament Composition pharmaceutique comprenant un ester de dha destinee a etre administree par voie parenterale
FR2963790B1 (fr) * 2010-08-11 2012-09-28 Pf Medicament Docosahexaeneoate de panthenyle et son utilisation dans le traitement et la prevention des maladies cardiovasculaires

Also Published As

Publication number Publication date
BR112015012102A2 (pt) 2017-07-11
WO2014083059A1 (fr) 2014-06-05
ZA201503808B (en) 2016-07-27
MA38113A1 (fr) 2016-09-30
EP2925311A1 (fr) 2015-10-07
FR2998479A1 (fr) 2014-05-30
IL238954A0 (en) 2015-07-30
TN2015000199A1 (fr) 2016-10-03
MX2015006685A (es) 2015-08-20
US20150306056A1 (en) 2015-10-29

Similar Documents

Publication Publication Date Title
FR25C1016I1 (fr) Utilisation de l'inhibiteur de la télomérase imetelstat pour le traitement du syndrome myélodysplasique
EP2818483A4 (fr) Composition médicinale pour le traitement et/ou la prévention du cancer
EP2532680A4 (fr) Composition médicinale pour le traitement et/ou la prévention du cancer
EP2934512A4 (fr) Utilisation de cannabinoïdes et de terpènes pour le traitement d'une toxicité d'organophosphate et de carbamate
MA40008A (fr) Antagoniste actrii pour le traitement et la prevention d'un ulcere cutane chez un sujet ayant l'anemie
EP2968160A4 (fr) Particules de modification immunitaire pour le traitement d'inflammation
EP2836226A4 (fr) Compositions et méthodes pour le traitement d'hémoglobinopathies
EP2830646A4 (fr) Compositions et méthodes d'utilisation pour le traitement de troubles métaboliques
EP2818482A4 (fr) Composition pharmaceutique pour le traitement et/ou la prévention du cancer
EP2931268A4 (fr) Compositions de gamma-hydroxybutyrate et leur utilisation pour le traitement de troubles
EP2818481A4 (fr) Composition pharmaceutique pour le traitement et/ou la prévention du cancer
EP2824114A4 (fr) Composition pharmaceutique pour le traitement et/ou la prévention du cancer
EP2814509A4 (fr) Anticorps dirigés contre l'intégrine v 6 et leur utilisation pour le traitement du cancer
EP2755676A4 (fr) Composition et pansement pour le traitement de blessures
EP2983619A4 (fr) Logiciel d'orientation et de planification chirurgicales pour le traitement de l'astigmatisme
EP2882849A4 (fr) Micro-tissus adipeux bruns injectables pour le traitement et la prévention de l'obésité et du diabète
FR3013184B1 (fr) Utilisation d'hydroxyapatite pour le traitement de l'esca
EP2911753A4 (fr) Dispositif de thérapie pour la prévention et le traitement du trismus
EP3025716A4 (fr) Substance pour le traitement ou le soulagement de la douleur
EP2726509A4 (fr) Utilisation d'anticorps agonistes anti-cd83 pour le traitement de maladies auto-immunes
EP2870161A4 (fr) Oxabicycloheptanes et oxabicycloheptènes pour le traitement d'une lésion de reperfusion
EP2702992A4 (fr) Utilisation de mélatonine pour le traitement et/ou la prévention de la mucosite
EP2823823A4 (fr) Utilisation de polypeptides dans la préparation de médicaments pour le traitement ou la prévention de la polyarthrite rhumatoïde
FR2999191B1 (fr) Souches probiotiques pour le traitement et/ou la prevention de la diarrhee
EP2854910A4 (fr) Niveaux de céramide dans le traitement et la prévention d'infections

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

ST Notification of lapse

Effective date: 20180731